BioSpace News Archive

Ashvattha Therapeutics announced that Jeffrey Cleland, Ph.D., Chairman, CEO & President of Ashvattha, will provide a corporate overview followed by a moderated Q&A at the UBS Global Healthcare Conference 2022 taking place in New York, NY, May 23-25, 2022.

Arcutis Biotherapeutics, Inc. reported the grant of an aggregate of 135,900 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 324,200 shares of Arcutis’ common stock to 49 newly hired employees.

Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the first quarter ended March 31, 2022 and provided a business update.

Neoleukin Therapeutics, Inc. announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in two upcoming investor conferences.

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of gamma-delta T cell therapies, today announced the Company’s new induced pluripotent stem cell (iPSC) based gamma-delta T cell platform.

AUM Biosciences announced that it has entered into a clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA, a premier global research-intensive biopharmaceutical company, to evaluate AUM001 in combination with MSD’s anti-PD-1 therapy, KEYTRUDA, in a global Phase 2 trial in patients with microsatellite stable colorectal cancer.

Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, today announced that it has completed development of its proprietary TheraSure™ Transplant Monitoring test for liver transplant patients.

Surrozen, Inc. today announced that Craig Parker, President and Chief Executive Officer, will present at the BofA Securities 2022 Healthcare Conference at 4 p.m. PT on Wednesday, May 11.

Keros Therapeutics, Inc. today provided a business update and reported financial results for the quarter ended March 31, 2022.

Belite Bio , Inc presented interim results of a Phase 1b/2 study of LBS-008 in adolescent STGD1 at The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2022.